Unlocking Hope for Cancer Patients Using PDT
PETER MAC COMBINATION ICI AND INV043 STUDY
FINDINGS AND IMPLICATIONS
.
• Combination therapy using INV043 with ICIs led to -80% control of ASCC tumours at study endpoint,
compared with ICI therapy alone, which achieved -12% control. Results were statistically significant
Mice under combination treatment maintained healthy weight with no negative side effects noted
Opens additional treatment options for upcoming clinical trial programs that span multiple cancers
ASCC has potential for orphan designation - leading to an expedited regulatory approval process
Findings reinforce potential for collaboration partnerships using combination therapies to extend the
patent life of blockbuster ICIs
•
AVERAGE TUMOUR VOLUMES SUBSTANTIALLY
LOWER IN COMBINATION TREATMENT GROUP
Average tumour volume post treatment
2000-
STANDALONE INV043 EXHIBITED LOWER
TUMOUR VOLUMES THAN STANDALONE ICIS
Tumour Volume (mm³)
2000
1500-
1000
500-
INV043 and PD-1
showed significant
decrease in average
tumour size
Tumour Volume (mm³)
1500-
1000-
500-
FFFF
1 7
INVO43 PD-1
INVO43
― Vehicle
_ Isotype Control
PD-1
Vehicle Isotype Control
13 19 25 31 37 43 49 60
Days post 1st treatment
PD-1 alone reached ethical
endpoint (tumours
>1500mm) except one
where tumour was controlled
3 7 11 15
INVO43
✰ Vehicle
19 23 27 31 35 39 43 47 51 60
Day post 1st treatment
Isotype Control (1/8)
PD-1 (1/8)
INVIONView entire presentation